GTx Inc. (GTXI)

1.16 +0.03 (+2.655%)

IEX Real-Time Price

April 23, 2019 EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.13

Price Open 1.13

Volume: 71,101

Avg Volume: 324,819

Market Cap: 27.9M

P/E Ratio -

52 Wk Range 0.74-25.6



GTXI Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
12.61M
3.99M
0.72
31.62%

2018-09-28
12.61M
1.96M
0.92
15.58%

2018-09-14
12.61M
1.98M
8.66
15.74%

2018-08-31
12.61M
2M
12.57
15.87%




GTXI Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2019-04-01
Q4 2018
N/A
0.00 (2)
0.00
0.00

2019-03-11
Q4 2018
N/A
-0.22 (2)
0.00
0.00

2018-10-22
Q3 2018
N/A
-0.30 (2)
-0.39
-0.09

2018-08-14
Q2 2018
N/A
-0.43 (2)
-0.43
0.00

News

INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition (2019-04-01 19:07 PR Newswire)

NEW YORK , April 1, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating: Coty, Inc. (NYSE:COTY)("Coty…

 

Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company (2019-03-22 14:14 PR Newswire)

NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered an active agent to their placebo group during the Vascepa tr…

 


Statistics

Shares Outstanding: 24.05M

Top 15 Institution Percent: 18.60

Price To Sales: N/A

Price To Book: 1.05

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -99.07

Return On Equity: -119.36

Profit Margin: N/A

Price History

Beta: 2.56

50-day Moving Avg: 1.17

200-day Moving Avg: 6.25

YTD Change: 31.82

5-day Change: -5.04

1-month Change: -5.83

3-month Change: 23.34

6-month Change: -35.06

1-year Change: -93.50

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: GTx Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.gtxinc.com

GTx Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of small molecules for treatment of cancer, including treatments for breast and prostate cancer and other medical conditions.